ASP3772 Pneumococcal Vaccine Description
ASP3772 utilizes the Multiple Antigen Presenting System (MAPS) platform which is Affinivax’s proprietary, next-generation vaccine technology. The MAPS technology platform uses proprietary chemistry that capitalizes on the highly specific and durable non-covalent, affinity binding between biotin and rhizavidin, a biotin-binding protein.
The highly stable MAPS complex created by this affinity binding contributes to a simple, modular, and efficient approach to the development of novel vaccines and immunotherapies.
Conventional vaccine conjugation technology seeks to optimize the generation of protective antibody responses mainly to polysaccharide antigens, using the protein antigen as a carrier. In stark contrast, a MAPS vaccine can present both the polysaccharide and the protein antigens to the host immune system to induce both a B- and T-cell immune response.
This unique capability of the MAPS technology allows for the tailored development of each MAPS vaccine or immunotherapy based on the specific type of immune response that is most desired for each pathogen and disease.
Affinivax is advancing a next-generation technology platform to enable the development of vaccines and immunotherapies
ASP3772 Pneumococcal Vaccine Indication
ASP3772 is a vaccine candidate that offers the potential to provide broader protection against pneumococcal disease.
ASP3772 Pneumococcal Vaccine Dosage
Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
ASP3772 Pneumococcal Vaccine Development News
- April 23, 2020: Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies.
- February 13, 2019: The first subject was dosed with ASP3772, a novel MAPS vaccine targeting Streptococcus pneumoniae (pneumococcal). This followed the successful submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in December 2018.
- February 28, 2017: Affinivax, Inc. and Astellas Pharma Inc. announced they have entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae (pneumococcus).
ASP3772 Pneumococcal Vaccine Clinical Trials
Clinical Trial NCT03803202: A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine (Recruiting).
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in adults 18 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator PCV13 in elderly 65 to 85 years of age.
In addition, Stage 2 will evaluate the immunogenicity of 3 different dose levels of ASP3772 relative to the response seen following administration of Pneumovax® 23 (PPSV23) for the serotypes not included in PCV13.